NHG-Richtlijnen
NHG-Standaard
M109
2.0
april 2018
april 2018
U. Urinewegen

Richtlijnen diagnostiek

Naar Volledige tekst ›

Anamnese

Naar Volledige tekst ›

Lichamelijk onderzoek

Naar Volledige tekst ›

Aanvullend onderzoek

Naar Volledige tekst ›

Evaluatie

Naar Volledige tekst ›

Richtlijnen Beleid

Naar Volledige tekst ›

Voorlichting

Naar Volledige tekst ›

Niet-medicamenteuze behandeling

Naar Volledige tekst ›

Medicamenteuze behandeling

Naar Volledige tekst ›

Kader Medicatiebewaking

Naar Volledige tekst ›

Controles

Naar Volledige tekst ›

Consultatie en verwijzing

Naar Volledige tekst ›

Kernboodschappen

Naar Samenvatting ›

Belangrijkste wijzigingen

Naar Samenvatting ›

Inleiding

Naar Samenvatting ›

Scope

Naar Samenvatting ›

Buiten de scope

Naar Samenvatting ›

Samenwerking en afstemming

Naar Samenvatting ›

Achtergronden

Naar Samenvatting ›

Begrippen

Naar Samenvatting ›

Epidemiologie

Naar Samenvatting ›

Etiologie en prognose

Naar Samenvatting ›

Pathofysiologie

Naar Samenvatting ›

Metabole complicaties

Naar Samenvatting ›

Nierfunctie

Naar Samenvatting ›

Richtlijnen diagnostiek

Naar Samenvatting ›

Anamnese

Naar Samenvatting ›

Lichamelijk onderzoek

Naar Samenvatting ›

Aanvullend onderzoek

Naar Samenvatting ›

Overig aanvullend onderzoek

Naar Samenvatting ›

Urinesediment

Naar Samenvatting ›

Lipidenspectrum en glucose

Naar Samenvatting ›

Schatting van de nierfunctie op basis van cystatine C

Naar Samenvatting ›

Point-of-care-creatininebepaling

Naar Samenvatting ›

Opsporing van metabole complicaties

Naar Samenvatting ›

Echografie

Naar Samenvatting ›

Evaluatie

Naar Samenvatting ›

Richtlijnen beleid

Naar Samenvatting ›

Voorlichting

Naar Samenvatting ›

Thuisarts

Naar Samenvatting ›

Zelfmanagement

Naar Samenvatting ›

Niet-medicamenteuze behandeling

Naar Samenvatting ›

Leefstijladviezen

Naar Samenvatting ›

Beleid bij patiënten met dreigende dehydratie

Naar Samenvatting ›

Vaccinatieadviezen

Naar Samenvatting ›

Medicamenteuze behandeling

Naar Samenvatting ›

Kader Medicatiebewaking

Naar Samenvatting ›

Beleid ten aanzien van het verhoogde cardiovasculaire risico

Naar Samenvatting ›
Patiënten met chronische nierschade en diabetes mellitus
Naar Samenvatting ›
Patiënten met chronische nierschade en verhoogde bloeddruk
Naar Samenvatting ›
Patiënten met een LDL ≥ 2,6 mmol/l
Naar Samenvatting ›
Patiënten met bekende hart- en vaatziekten
Naar Samenvatting ›

Controle

Naar Samenvatting ›

Metabole complicaties

Naar Samenvatting ›

Beleid bij eindstadium nierfalen

Naar Samenvatting ›

Consultatie en verwijzing

Naar Samenvatting ›

Bijlage 1 Beleid bij chronische nierschade afhankelijk van stadiëring

Naar Samenvatting ›

Referenties

  1. Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL, Den Heijer M. Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen biomedical study. Kidney Int 2007;72:632-7.
  2. Crop MJ, De Rijke YB, Verhagen PCMS, Cransberg K, Zietse R. Diagnostic value of urinary dysmorphic erythrocytes in clinical practice. Nephron Clin Pract 2010;115:c203-12.
  3. Van der Snoek BE, Hoitsma AJ, Van Weel C, Koene RA. Dysmorfe erytrocyten in het urinesediment bij het onderscheiden van urologische en nefrologische oorzaken van hematurie. Ned Tijdschr Geneeskd 1994;138:721-6.
  4. ECLM. European urinalysis guidelines. Scan J Clin Lab Invest 2000:1-96.
  5. Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis. Biochem Med (Zagreb) 2014;24:89-104.
  6. Hooijkaas H, Mohrmann K, Souverijn JHM, Smeets L. Handboek medische laboratoriumdiagnostiek. Houten: Prelum Uitgevers, 2013.
  7. KDIGO. Kidney disease improving global outcomes. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International 2013;3:S1-150.
  8. Bakker AJ. Screening op microalbuminurie: aanbevelingen voor urineverzameling, conservering en analyse. Ned Tijdschr Klin Chem 1998;23:129-37.
  9. De Grauw WJC, Kaasjager HAH, Bilo HJG, Faber EF, Flikweert S†, Gaillard CAJM, et al. Landelijke Transmurale Afspraak Chronische nierschade. Huisarts Wet 2009;52:586-97.
  10. Matsushita K, Van der Velde M, Astor BC, Woodward M, Levey AS, De Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-81.
  11. Astor BC, Matsushita K, Gansevoort RT, Van der Velde M, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011;79:1331-40.
  12. European Society of Cardiology. European Guidelines on cardiovascular disease prevention in clinical practice (2016). Eur Heart J 2016; 37:2315-81.
  13. Gansevoort RT, Matsushita K, Van der Velde M, Astor BC, Woodward M, Levey AS, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 2011;80:93-104.
  14. Van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011;79:1341-52.
  15. Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015;3:514-25.
  16. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012;380:807-14.
  17. De Zeeuw D, Hillege HL, De Jong PE. The kidney, a cardiovascular risk marker, and a new target for therapy. Kidney Int Suppl 2005:S25-9.
  18. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult us population: third national health and nutrition examination survey. Am J Kidney Dis 2003;41:1-12.
  19. Levey AS, De Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int 2011;80:17-28.
  20. Van Gelder VA, Scherpbier-De Haan ND, De Grauw WJ, Vervoort GM, Van Weel C, Biermans MC, et al. Quality of chronic kidney disease management in primary care: a retrospective study. Scand J Prim Health Care 2016;34:73-80.
  21. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States renal data system. J Am Soc Nephrol 2007;18:2644-8.
  22. Gansevoort RT, Van der Heij B, Stegeman CA, De Charro FT, Nieuwenhuizen MG, De Zeeuw D, et al. Trends in the incidence of treated end-stage renal failure in The Netherlands: hope for the future? Kidney Int Suppl 2004:S7-10.
  23. Stengel B, Billon S, Van Dijk PC, Jager KJ, Dekker FW, Simpson K, et al. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant 2003;18:1824-33.
  24. Van Dijk PC, Jager KJ, Stengel B, Gronhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int 2005;67:1489-99.
  25. Tanner RM, Brown TM, Muntner P. Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease. Curr Hypertens Rep 2012;14:152-9.
  26. Scherpbier ND, De Grauw WJ, Wetzels JF, Vervoort GM. Acute nierinsufficiëntie bij combinatie raas-remmer en dehydratie. Ned Tijdschr Geneeskd 2010;154:A1548.
  27. Stirling C, Houston J, Robertson S, Boyle J, Allan A, Norrie J, et al. Diarrhoea, vomiting and ACE inhibitors: an important cause of acute renal failure. J Hum Hypertens 2003;17:419-23.
  28. Foley RN. Clinical epidemiology of cardiovascular disease in chronic kidney disease. J Ren Care 2010;36 Suppl 1:4-8.
  29. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013;382:339-52.
  30. Wanner C, Amann K, Shoji T. The heart and vascular system in dialysis. Lancet 2016;388:276-84.
  31. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.
  32. Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. Jama 2012;307:1941-51.
  33. Van Gelder VA, Scherpbier-De Haan ND, De Grauw WJ, O’Callaghan CA, Wetzels JF, Lasserson DS. Impact on cardiovascular risk follow-up from a shift to the CKD-EPI formula for EGFR reporting: a cross-sectional population-based primary care study. BMJ Open 2013;3:e003631.
  34. Van den Brand JA, Van den Boekel GA, Willems HL, Kiemeney LA, Den Heijer M, Wetzels F. Introduction of the CKD-EPI equation to estimate glomerular filtration rate in a Caucasian population. Nephrol Dial Transplant 2011:3176-81.
  35. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-54.
  36. Fraser CG. Reference change values. Clin Chem Lab Med 2012;50:807-12.
  37. Bakker AJ, De Grauw WJ. Methoden van urineverzameling voor het bepalen van microalbuminurie: tijd voor consensus. Ned Tijdschr Geneeskd 2004;148:2012-5.
  38. De Grauw WJ, Van de Lisdonk EH, Van de Hoogen HJ, Van Gerwen WH, Van den Bosch WJ, Willems JL, et al. Screening for microalbuminuria in type 2 diabetic patients: the evaluation of a dipstick test in general practice. Diabet Med 1995;12:657-63.
  39. Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A. Cystatin c as a marker of GFR: history, indications, and future research. Clin Biochem 2005;38:1-8.
  40. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin c. N Engl J Med 2012;367:20-9.
  41. Levey AS, Inker LA, Coresh J. GFR estimation: from physiology to public health. Am J Kidney Dis 2014;63:820-34.
  42. Scherpbier-De Haan ND, Van Gelder VA, Van Weel C, Vervoort GM, Wetzels JF, De Grauw WJ. Initial implementation of a web-based consultation process for patients with chronic kidney disease. Ann Fam Med 2013;11:151-6.
  43. Van Gelder VA, Scherpbier-De Haan ND, Van Berkel S, Akkermans RP, De Grauw IS, Adang EM, et al. Web-based consultation between general practitioners and nephrologists: a cluster randomized controlled trial. Fam Pract 2017;34:430-6.
  44. Haley WE, Beckrich AL, Sayre J, McNeil R, Fumo P, Rao VM, et al. Improving care coordination between nephrology and primary care: a quality improvement initiative using the renal physicians association toolkit. Am J Kidney Dis 2015;65:67-79.
  45. Lee BJ, Forbes K. The role of specialists in managing the health of populations with chronic illness: the example of chronic kidney disease. BMJ 2009;339:b2395.
  46. Geerts AF, De Koning FH, De Vooght KM, Egberts AC, De Smet PA, Van Solinge WW. Feasibility of point-of-care creatinine testing in community pharmacy to monitor drug therapy in ambulatory elderly patients. J Clin Pharm Ther 2013;38:416-22.
  47. Shephard M, Peake M, Corso O, Shephard A, Mazzachi B, Spaeth B, et al. Assessment of the nova statsensor whole blood point-of-care creatinine analyzer for the measurement of kidney function in screening for chronic kidney disease. Clin Chem Lab Med 2010;48:1113-9.
  48. Kosack CS, De Kieviet W, Bayrak K, Milovic A, Page AL. Evaluation of the Nova StatSensor®Xpress(TM) creatinine point-of-care handheld analyzer. PLoS One 2015;10:e0122433.
  49. Avila M, Floris A, Staal S, Rios A, Eijkel J, Van den Berg A. Point of care creatinine measurement for diagnosis of renal disease using a disposable microchip. Electrophoresis 2013;34:2956-61.
  50. Lomakin FM, Tobar C. Accuracy of point-of-care serum creatinine devices for detecting patients at risk of contrast-induced nephropathy: a critical overview. Crit Rev Clin Lab Sci 2014;51:332-43.
  51. Haneder S, Gutfleisch A, Meier C, Brade J, Hannak D, Schoenberg SO, et al. Evaluation of a handheld creatinine measurement device for real-time determination of serum creatinine in radiology departments. World J Radiol 2012;4:328-34.
  52. Morita S, Suzuki K, Masukawa A, Ueno E. Assessing renal function with a rapid, handy, point-of-care whole blood creatinine meter before using contrast materials. Jpn J Radiol 2011;29:187-93.
  53. Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 2009;20:205-12.
  54. CBO. Zorgmodule zelfmanagement 1.0 (2014). Ga naar bron
  55. NIVEL. Zelfmanagement door mensen met chronische ziekten. Kennissynthese van onderzoek en implementatie in Nederland (2015). Ga naar bron
  56. Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, et al. Shared decision making: a model for clinical practice. J Gen Intern Med 2012;27:1361-7.
  57. Schipper K, Van der Borg WE, De Jong-Camerik J, Abma TA. Living with moderate to severe renal failure from the perspective of patients. BMC Nephrol 2016;17:48.
  58. Van Huffel L, Tomson CR, Ruige J, Nistor I, Van Biesen W, Bolignano D. Dietary restriction and exercise for diabetic patients with chronic kidney disease: a systematic review. PLoS One 2014;9:e113667.
  59. Morales E, Valero MA, Leon M, Hernandez E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003;41:319-27.
  60. Solerte SB, Fioravanti M, Schifino N, Ferrari E. Effects of diet-the-rapy on urinary protein excretion albuminuria and renal haemodynamic function in obese diabetic patients with overt nephropathy. Int J Obes 1989;13:203-11.
  61. Saiki A, Nagayama D, Ohhira M, Endoh K, Ohtsuka M, Koide N, et al. Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J Obes (Lond) 2005;29:1115-20.
  62. Vasquez B, Flock EV, Savage PJ, Nagulesparan M, Bennion LJ, Baird HR, et al. Sustained reduction of proteinuria in type 2 (non-insulin-dependent) diabetes following diet-induced reduction of hyperglycaemia. Diabetologia 1984;26:127-33.
  63. Gilardini L, Zulian A, Girola A, Redaelli G, Conti A, Invitti C. Predictors of the early impairment of renal disease in human obesity. Int J Obes (Lond) 2010;34:287-94.
  64. Shen WW, Chen HM, Chen H, Xu F, Li LS, Liu ZH. Obesity-related glomerulopathy: body mass index and proteinuria. Clin J Am Soc Nephrol 2010;5:1401-9.
  65. Leehey DJ, Moinuddin I, Bast JP, Qureshi S, Jelinek CS, Cooper C, et al. Aerobic exercise in obese diabetic patients with chronic kidney disease: a randomized and controlled pilot study. Cardiovasc Diabetol 2009;8:62.
  66. Bolignano D, Zoccali C. Effects of weight loss on renal function in obese CKD patients: a systematic review. Nephrol Dial Transplant 2013;28 Suppl 4:iv82-98.
  67. Sah SK, Siddiqui MA, Darain H. Effect of progressive resistive exercise training in improving mobility and functional ability of middle adulthood patients with chronic kidney disease. Saudi J Kidney Dis Transpl 2015;26:912-23.
  68. Heiwe S, Jacobson SH. Exercise training in adults with CKD: a systematic review and meta-analysis. Am J Kidney Dis 2014;64:383-93.
  69. Barcellos FC, Santos IS, Umpierre D, Bohlke M, Hallal PC. Effects of exercise in the whole spectrum of chronic kidney disease: a systematic review. Clin Kidney J 2015;8:753-65.
  70. Painter P, Roshanravan B. The association of physical activity and physical function with clinical outcomes in adults with chronic kidney disease. Curr Opin Nephrol Hypertens 2013;22:615-23.
  71. Elihimas UF, Jr., Elihimas HC, Lemos VM, Leao Mde A, Sa MP, Franca EE, et al. Smoking as risk factor for chronic kidney disease: Systematic review. J Bras Nefrol 2014;36:519-28.
  72. Clase C. Renal failure (chronic). BMJ Clin Evid 2011.
  73. Bleyer AJ, Shemanski LR, Burke GL, Hansen KJ, Appel RG. Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. Kidney Int 2000;57:2072-9.
  74. Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994;17:126-31.
  75. Johnson DW. Evidence-based guide to slowing the progression of early renal insufficiency. Intern Med J 2004;34:50-7.
  76. McMahon EJ, Campbell KL, Bauer JD, Mudge DW. Altered dietary salt intake for people with chronic kidney disease. Cochrane Database Syst Rev 2015;2:Cd010070.
  77. Ash S, Campbell KL, Bogard J, Millichamp A. Nutrition prescription to achieve positive outcomes in chronic kidney disease: a systematic review. Nutrients 2014;6:416-51.
  78. Gezondheidsraad. Richtlijnen goede voeding 2015. Den Haag: Gezondheidsraad, 2015; publicatienr. 2015/24. Ga naar bron
  79. Kopple JD. Do low-protein diets retard the loss of kidney function in patients with diabetic nephropathy? Am J Clin Nutr 2008;88:593-4.
  80. Kaysen GA, Odabaei G. Dietary protein restriction and preservation of kidney function in chronic kidney disease. Blood Purif 2013;35:22-5.
  81. Rughooputh MS, Zeng R, Yao Y. Protein diet restriction slows chronic kidney disease progression in non-diabetic and in type 1 diabetic patients, but not in type 2 diabetic patients: a meta-analysis of randomized controlled trials using glomerular filtration rate as a surrogate. PLoS One 2015;10:e0145505.
  82. Nezu U, Kamiyama H, Kondo Y, Sakuma M, Morimoto T, Ueda S. Effect of low-protein diet on kidney function in diabetic nephropathy: meta-analysis of randomised controlled trials. BMJ Open 2013;3.
  83. Robertson L, Waugh N, Robertson A. Protein restriction for diabetic renal disease. Cochrane Database Syst Rev 2007:CD002181.
  84. Fouque D, Laville M. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev 2009:Cd001892.
  85. Abraham G, Ghosh S. Role of pneumococcal vaccination in renal diseases. J Assoc Physicians India 2015;63:36-7.
  86. Choudhury D, Luna-Salazar C. Preventive health care in chronic kidney disease and end-stage renal disease. Nat Clin Pract Nephrol 2008;4:194-206.
  87. Dalrymple LS, Go AS. Epidemiology of acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(5):1487–1493. doi:10.2215/CJN.01290308
  88. Grzegorzewska AE. Prophylactic vaccinations in chronic kidney disease: current status. Hum Vaccin Immunother 2015;11:2599-605.
  89. Mastalerz-Migas A, Steciwko A, Brydak LB. Immune response to influenza vaccine in hemodialysis patients with chronic renal failure. Adv Exp Med Biol 2013;756:285-90.
  90. Mathew R, Mason D, Kennedy JS. Vaccination issues in patients with chronic kidney disease. Expert Rev Vaccines 2014;13:285-98.
  91. Principi N, Esposito S. Influenza vaccination in patients with end-stage renal disease. Expert Opin Drug Saf 2015;14:1249-58.
  92. Soni R, Horowitz B, Unruh M. Immunization in end-stage renal disease: opportunity to improve outcomes. Semin Dial 2013;26:416-26.
  93. Mahmoodi M, Aghamohammadi A, Rezaei N, Lessan-Pezeshki M, Pourmand G, Mohagheghi MA, et al. Antibody response to pneumococcal capsular polysaccharide vaccination in patients with chronic kidney disease. Eur Cytokine Netw 2009;20:69-74.
  94. Watcharananan SP, Thakkinstian A, Srichunrasmee C, Chuntratita W, Sumethkul V. Comparison of the immunogenicity of a monovalent influenza A/H1N1 2009 vaccine between healthy individuals, patients with chronic renal failure, and immunocompromised populations. Transplant Proc 2014;46:328-31.
  95. Snyder JJ, Collins AJ. Association of preventive health care with atherosclerotic heart disease and mortality in CKD. J Am Soc Nephrol 2009;20:1614-22.
  96. Wang IK, Lin CL, Lin PC, Liang CC, Liu YL, Chang CT, et al. Effectiveness of influenza vaccination in patients with end-stage renal disease receiving hemodialysis: a population-based study. PLoS One 2013;8:e58317.
  97. Vandecasteele SJ, Ombelet S, Blumental S, Peetermans WE. The ABC of pneumococcal infections and vaccination in patients with chronic kidney disease. Clin Kidney J 2015;8:318-24.
  98. Remschmidt C, Wichmann O, Harder T. Influenza vaccination in patients with end-stage renal disease: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness, and safety. BMC Med 2014;12:244.
  99. Chen CI, Kao PF, Wu MY, Fang YA, Miser JS, Liu JC, et al. Influenza vaccination is associated with lower risk of acute coronary syndrome in elderly patients with chronic kidney disease. Medicine (Baltimore) 2016;95:e2588.
  100. Gezondheidsraad. Vaccinatie tegen pneumokokken bij ouderen en risicogroepen (2003). Ga naar bron
  101. Gezondheidsraad. Briefadvies Vaccinatie tegen seizoensgriep. Den Haag: Gezondheidsraad, 2011; publicatienr. 2011/21. Ga naar bron
  102. HASP. Richtlijn informatie-uitwisseling tussen huisarts en specialist (2017). Ga naar bron
  103. FMS. Leidraad overdracht van medicatiegegevens. Ga naar bron
  104. EMA. Note for guidance of the evaluation of the pharmokinetics of medicinal productin patients with impaired renal function (2004). Ga naar bron
  105. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
  106. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on micro-vascular outcomes in type 2 diabetes: an analysis of the accord randomised trial. Lancet 2010;376:419-30.
  107. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
  108. Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/ epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009;169:1307-16.
  109. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. Lancet 1998;352:837-53.
  110. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957-67.
  111. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435-43.
  112. The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. New Engl J Med 2015; 373;2103-16.
  113. Anonymus. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Uk prospective diabetes study group. BMJ 1998;317:703-13.
  114. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Hot study group. Lancet 1998;351:1755-62.
  115. Cushman WC, Evans GW, Byington RP, Goff DC, Jr., Grimm RH, Jr., Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes ong patients with chronic kidney disease. Clin J Am Soc Nephrol 2008;3:1487-93.
  116. Schrier RW, Estacio RO, Mehler PS, Hiatt WR. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol 2007;3:428-38.
  117. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. J Am Soc Nephrol 2005;16:2170-9.
  118. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-9.
  119. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil-trando-lapril study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16.
  120. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-40.
  121. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91.
  122. Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, et al. Effects of intensive BP control in CKD. J Am Soc Nephrol 2017;28:2812-23.
  123. NICE. Chronic kidney disease. Early identification and management of chronic kidney disease in adults in primary and secondary care (2015). Ga naar bron
  124. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72.
  125. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-219.
  126. Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M, et al. Chronic kidney disease and prevalent atrial fibrillation: the chronic renal insufficiency cohort (CRIC). Am Heart J 2010;159:1102-7.
  127. Young JH, Klag MJ, Muntner P, Whyte JL, Pahor M, Coresh J. Blood pressure and decline in kidney function: findings from the systolic hypertension in the elderly program (SHEP). J Am Soc Nephrol 2002;13:2776-82.
  128. Musini VM, Tejani AM, Bassett K, Wright JM. Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev 2009:Cd000028.
  129. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009;20:1069-77.
  130. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003;139:901-6.
  131. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-36.
  132. Mann JF, Gerstein HC, Yi QL, Lonn EM, Hoogwerf BJ, Rashkow A, et al. Development of renal disease in people at high cardiovascular risk: results of the hope randomized study. J Am Soc Nephrol 2003;14:641-7.
  133. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Jr., Whelton PK, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Arch Intern Med 2005;165:936-46.
  134. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr., Whelton PK, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006;144:172-80.
  135. Apperloo AJ, De Zeeuw D, De Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997;51:793-7.
  136. Buter H, Hemmelder MH, Navis G, De Jong PE, De Zeeuw D. The blunting of the antiproteinuric efficacy of ace inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998;13:1682-5.
  137. Van der Kleij FG, Schmidt A, Navis GJ, Haas M, Yilmaz N, De Jong PE, et al. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status. Kidney Int Suppl 1997;63:S23-6.
  138. Vogt L, Waanders F, Boomsma F, De Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008;19:999-1007.
  139. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53.
  140. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
  141. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? Expert Opin Pharmacother 2015;16:1449-61.
  142. Erickson KF, Japa S, Owens DK, Chertow GM, Garber AM, Goldhaber-Fiebert JD. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease. J Am Coll Cardiol 2013;61:1250-8.
  143. Geng Q, Ren J, Song J, Li S, Chen H. Meta-analysis of the effect of statins on renal function. Am J Cardiol 2014;114:562-70.
  144. Zhang Z, Wu P, Zhang J, Wang S, Zhang G. The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: a meta-analysis. Pharmacol Res 2016;105:74-83.
  145. Barylski M, Nikfar S, Mikhailidis DP, Toth PP, Salari P, Ray KK, et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy: a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res 2013;72:35-44.
  146. Yan YL, Qiu B, Wang J, Deng SB, Wu L, Jing XD, et al. High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis. BMJ Open 2015;5:e006886.
  147. Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;157:251-62.
  148. Zhang YF, He F, Ding HH, Dai W, Zhang Q, Luan H, et al. Effect of uric-acid-lowering therapy on progression of chronic kidney disease: a meta-analysis. J Huazhong Univ Sci Technolog Med Sci 2014;34:476-81.
  149. Savarese G, Musella F, Volpe M, Paneni F, Perrone-Filardi P. Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis. Int J Cardiol 2013;167:2482-9.
  150. Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J 2013;34:1807-17.
  151. Galvao TF, Araujo ME, Penha AP, Silva MT. Statins for early stage chronic kidney disease: an overview of reviews. Cardiovasc Hematol Disord Drug Targets 2014;14:205-11.
  152. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009:Cd007784.
  153. Nikolic D, Banach M, Nikfar S, Salari P, Mikhailidis DP, Toth PP, et al. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Int J Cardiol 2013;168:5437-47.
  154. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012a;157:263-75.
  155. Sanguankeo A, Upala S, Cheungpasitporn W, Ungprasert P, Knight EL. Effects of statins on renal outcome in chronic kidney disease patients: a systematic review and meta-analysis. PLoS One 2015;10:e0132970.
  156. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92.
  157. Su X, Zhang L, Lv J, Wang J, Hou W, Xie X, et al. Effect of statins on kidney disease outcomes: a systematic review and meta-analysis. Am J Kidney Dis 2016;67:881-92.
  158. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 1998;32:S142-56.
  159. Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: an open letter to the adult treatment panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes 2012;5:2-5.
  160. Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A. Monitoring cholesterol levels: measurement error or true change? Ann Intern Med 2008;148:656-61.
  161. Takahashi O, Glasziou PP, Perera R, Shimbo T, Suwa J, Hiramatsu S, et al. Lipid re-screening: what is the best measure and interval? Heart 2010;96:448-52.
  162. Weigert AL, Schafer AI. Uremic bleeding: pathogenesis and therapy. Am J Med Sci 1998;316:94-104.
  163. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003;42:201-8.
  164. Krause MW, Massing M, Kshirsagar A, Rosamond W, Simpson RJ, Jr. Combination therapy improves survival after acute myocardial infarction in the elderly with chronic kidney disease. Ren Fail 2004;26:715-25.
  165. McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 2002;144:226-32.
  166. Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med 2006;166:1884-91.
  167. Basra SS, Tsai P, Lakkis NM. Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. J Am Coll Cardiol 2011;58:2263-9.
  168. Harmon JP, Zimmerman DL, Zimmerman DL. Anticoagulant and antiplatelet therapy in patients with chronic kidney disease: risks versus benefits review. Curr Opin Nephrol Hypertens 2013;22:624-8.
  169. Jain N, Hedayati SS, Sarode R, Banerjee S, Reilly RF. Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence? Clin J Am Soc Nephrol 2013;8:665-74.
  170. Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012b;156:445-59.
  171. Chen JJ, Lin LY, Yang YH, Hwang JJ, Chen PC, Lin JL. Anti-platelet or anti-coagulant agent for the prevention of ischemic stroke in patients with end-stage renal disease and atrial fibrillation: a nation-wide database analyses. Int J Cardiol 2014;177:1008-11.
  172. Leng WX, Ren JW, Cao J, Cong YL, Cui H, Hu GL, et al. Chronic kidney disease: is it a true risk factor of reduced clopidogrel efficacy in elderly patients with stable coronary artery disease? Thromb Res 2013;131:218-24.
  173. Lin TH, Lai WT, Hsin HT, Li AH, Wang CL, Kuo CT, et al. Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry. PLoS One 2013;8:e71917.
  174. Lin L, Wang H, Chen YF, Lin WW, Wang CL, Lin CH. High maintenance dose of clopidogrel in patients with high on-treatment platelet reactivity after a percutaneous coronary intervention: a meta-analysis. Coron Artery Dis 2015;26:386-95.
  175. Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2013;2:Cd008834.
  176. Couchoud C, Labeeuw M, Moranne O, Allot V, Esnault V, Frimat L, et al. A clinical score to predict 6-month prognosis in elderly patients starting dialysis for end-stage renal disease. Nephrol Dial Transplant 2009;24:1553-61.
  177. Kurella Tamura M, Covinsky KE, Chertow GM, Yaffe K, Landefeld CS, McCulloch CE. Functional status of elderly adults before and after initiation of dialysis. N Engl J Med 2009;361:1539-47.
Chronische nierschade
Telenefrologie: webbased consultatiemogelijkheid
NHG-werkgroep
De Grauw W, De Leest K, Schenk P, Scherpbier-De Haan N, Tjin-A-Ton J, Tuut M, Van Balen J
5 gerelateerde lacunesGerelateerd onderzoek
E-mail